The accreditors of this session require that you periodically check in to verify that you are still attentive.
Please click the button below to indicate that you are.
Sp45
AUTOIMMUNE GASTRITIS: DIAGNOSIS AND MANAGEMENT
Date
May 6, 2023
Explore related products in the following collection:
Gastritis is frequently encountered by gastroenterologists in their evaluation of patients with foregut-related symptoms. There is an unmet need for GI clinicians to become familiar with the many types of gastritis given the several etiologies present, and the implications for treatment, prognosis, and surveillance. Gastric metaplasia, although uncommon in US populations, presents a quandary for practicing physicians given the general unfamiliarity with its classification, management and prognosis. Several novel endoscopic techniques have been proposed to improve the diagnosis of gastric preneoplastic lesions and help personalize and guide the most appropriate surveillance strategy. The purpose of this session is thus to familiarize clinicians with how to approach and manage the patient with gastritis and/or gastric atrophy/metaplasia with the aim of obtaining a definitive diagnosis, staging and grading the lesion, identifying the likely etiologic factor, and initiating appropriate treatment and surveillance.
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…